Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein that combines human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin with demonstrated anticancer activity [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein that combines human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin with demonstrated anticancer activity [1]. |
In vivo | Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; female NMRI nude mice MiaPaca-A2 xenografts) demonstrated antitumor activity against established pancreatic cancer [1]. |
Synonyms | L19-IL2 |
Molecular Weight | N/A |
CAS No. | 1957239-90-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bifikafusp alfa 1957239-90-5 L19-IL2 inhibitor inhibit